Autolus Therapeutics plc Stock News

Autolus Therapeutics (AUTL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

This week’s online annual meeting of the American Society for Gene and Cell Therapy will take place on the web.

Autolus Therapeutics PLC Sponsored ADR (AUTL) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in

As of late, it has definitely been a great time to be an investor Autolus Therapeutics

AUTO1 is uniquely positioned among CD19-targeted CAR-T products due to its fast off-rate kinetics. AUTO1 has low rates of cytokine release syndrome with better

It's been a pretty great week for Autolus Therapeutics plc (NASDAQ:AUTL) shareholders, with its shares surging 12% to...

AUTL earnings call for the period ending March 31, 2020.

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shares of Autolus Therapeutics (NASDAQ:AUTL) were unchanged at $10.28 after the company reported Q1 results.Quarterly Results Earnings per share rose 13.04% year over year to ($0.60), which beat the e

- Conference Call to be held on May 7, 2020 at 8:30 am EDT/1:30 pm BST- LONDON, May 07, 2020 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical.

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.) Adverum Biotechnologies Inc...

LONDON, May 01, 2020 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.

Shares of Autolus Therapeutics Ltd – (NASDAQ:AUTL) have received a consensus recommendation of “Buy” from the seven ratings firms that are covering the company, Marketbeat Ratings reports. One e

Goldman Sachs Group Inc. lessened its stake in Autolus Therapeutics Ltd – (NASDAQ:AUTL) by 55.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and

Wall Street brokerages expect Autolus Therapeutics Ltd – (NASDAQ:AUTL) to post sales of $1.15 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Autolus Ther